Literature DB >> 30701159

Role of the androgen signaling axis in genitourinary malignancies.

Brian M Shinder1, Adam Shupe1, Geun Taek Lee1, Mark N Stein2, Isaac Y Kim1, Eric A Singer1.   

Abstract

As we learn more about the molecular biology of genitourinary malignancies, novel therapeutic strategies can be developed. This is especially crucial for prostate, renal, and bladder cancer, where mortality rates remain high especially in advanced disease states. The androgen signaling axis and the androgen receptor (AR) are areas that are actively being explored for their role in these diseases. Although long been associated with prostate cancer development and progression, the role of AR in renal cell carcinoma (RCC) and bladder cancer is becoming recognized as well. This review will highlight the current research into the role of the androgen signaling axis in genitourinary malignancies and how this pathway is being used to expand our therapeutic armamentarium.

Entities:  

Keywords:  Androgen receptor (AR); bladder cancer; kidney cancer; prostate cancer

Year:  2018        PMID: 30701159      PMCID: PMC6349041          DOI: 10.21037/tcr.2018.03.41

Source DB:  PubMed          Journal:  Transl Cancer Res        ISSN: 2218-676X            Impact factor:   1.241


  41 in total

1.  Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.

Authors:  Charles Huggins; Clarence V Hodges
Journal:  J Urol       Date:  2002-02       Impact factor: 7.450

Review 2.  Overcoming persistent dependency on androgen signaling after progression to castration-resistant prostate cancer.

Authors:  Masuo Yamaoka; Takahito Hara; Masami Kusaka
Journal:  Clin Cancer Res       Date:  2010-07-20       Impact factor: 12.531

Review 3.  CYP17 inhibitors for prostate cancer therapy.

Authors:  Tadas S Vasaitis; Robert D Bruno; Vincent C O Njar
Journal:  J Steroid Biochem Mol Biol       Date:  2010-11-17       Impact factor: 4.292

4.  Abiraterone and increased survival in metastatic prostate cancer.

Authors:  Johann S de Bono; Christopher J Logothetis; Arturo Molina; Karim Fizazi; Scott North; Luis Chu; Kim N Chi; Robert J Jones; Oscar B Goodman; Fred Saad; John N Staffurth; Paul Mainwaring; Stephen Harland; Thomas W Flaig; Thomas E Hutson; Tina Cheng; Helen Patterson; John D Hainsworth; Charles J Ryan; Cora N Sternberg; Susan L Ellard; Aude Fléchon; Mansoor Saleh; Mark Scholz; Eleni Efstathiou; Andrea Zivi; Diletta Bianchini; Yohann Loriot; Nicole Chieffo; Thian Kheoh; Christopher M Haqq; Howard I Scher
Journal:  N Engl J Med       Date:  2011-05-26       Impact factor: 91.245

Review 5.  Androgen deprivation therapy for prostate cancer.

Authors:  Nima Sharifi; James L Gulley; William L Dahut
Journal:  JAMA       Date:  2005-07-13       Impact factor: 56.272

Review 6.  Early versus deferred androgen suppression in the treatment of advanced prostatic cancer.

Authors:  B Nair; T Wilt; R MacDonald; I Rutks
Journal:  Cochrane Database Syst Rev       Date:  2002

Review 7.  Androgen deprivation therapy for prostate cancer.

Authors:  Eric A Singer; Dragan J Golijanin; Hiroshi Miyamoto; Edward M Messing
Journal:  Expert Opin Pharmacother       Date:  2008-02       Impact factor: 3.889

Review 8.  Healthcare economics of bladder cancer: cost-enhancing and cost-reducing factors.

Authors:  Katia Noyes; Eric A Singer; Edward M Messing
Journal:  Curr Opin Urol       Date:  2008-09       Impact factor: 2.309

9.  The expression of vascular endothelial growth factor in transitional cell carcinoma of urinary bladder is correlated with cancer progression.

Authors:  Ching-Chiang Yang; Kang-Chu Chu; Wen-Meng Yeh
Journal:  Urol Oncol       Date:  2004 Jan-Feb       Impact factor: 3.498

10.  Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).

Authors:  Eric J Small; Susan Halabi; Nancy A Dawson; Walter M Stadler; Brian I Rini; Joel Picus; Preston Gable; Frank M Torti; Ellen Kaplan; Nicholas J Vogelzang
Journal:  J Clin Oncol       Date:  2004-03-15       Impact factor: 44.544

View more
  1 in total

1.  Urinary microbiome profile in men with genitourinary malignancies.

Authors:  Hyun Kyu Ahn; Kwangmin Kim; Junhyung Park; Kwang Hyun Kim
Journal:  Investig Clin Urol       Date:  2022-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.